Skip to content
MARKETS / NASDAQ / CDIO
NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

Cardio Diagnostics Holdings, Inc. CDIO

5 fiscal years on record · USD · FY2025 reported · SEC filings only
$14,825
▼ 57.5% YoY
$-6.5M
$-5.9M
In brief

What this company does

in March 2023, we announced the launch of our second product, PrecisionCHD™, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease. In May 2023, we launched CardioInnovate360™, a research-use-only (“RUO”) solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases. In February 2024, we announced the launch of HeartRisk™, a cardiovascular disease risk intelligence platform. As of March 13, 2026, we had 15 full-time employees and two part-time employees.

Written from the business description in Cardio Diagnostics Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 13 March 2026. Every sentence was checked against that document before publication.

Growth
USD 14,825.00
Revenue, FY2025 · full 5-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -6.5
-4M-8M20212022202320242025
Compound annual growth
+149.9%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−43832 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -43737.5% · Net -43832.5%
-200000%-400000%20212022202320242025
ROE
FY2025 · ROE -78.6%
-100%-200%20212022202320242025

Each USD of equity lost 79 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -5.9
-2.5M-5.0M20212022202320242025

Total assetsUSD 7.8M
EquityUSD 7.0M
CashUSD 0.00
Current ratio9.79×

Equity funds 90% of total assets.

The 5-year record
5 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021
Revenue $B0.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0·
Income tax $B···0.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0··
EPS, diluted $−3.71−9.35−0.66−1.51−0.53
Dividend / sh $·····
Payout %·····
ROE %−78.6−134.0−230.8−173.6−58.1
Shares out B0.000.000.020.010.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 20 reconciliationsAUDITED

Reconciled in 5 of 19 fiscal years. 56 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityIn Vitro & In Vivo Diagnostic Substances
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2021

Share this section

Download image